Colistimethate sodium
CAS : 30387-39-4
Ref. 3D-FBA38739
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- Colimicina
- Colimycin M
- Colimyscine
- Colistimethate
- Colistin sodium methanesulfonate
- Colistin sulfomethate
- Colistin sulfomethate sodium
- Colistinemethanesulfonate sodique
- Colistrimethate sodium
- Colomycin
- Voir d'autres synonymes
- Coly-Mycin M
- Coly-Mycin M Parenteral
- Coly-mycin
- Coly-mycin injectable
- Colymycin M
- Pentasodium colistinmethanesulfonate
- Sodium colistimethate
- Sodium colistin methanesulfonate
- Sodium colistinemethanesulfonate
- W 1929
- Colistinmethanesulfonic acid, sodium salt
- Pentasodium [(4-{[3-(1-Hydroxyethyl)-12,15-Bis(2-Methylpropyl)-2,5,8,11,14,17,20-Heptaoxo-6,9,18-Tris{2-[(Sulfonatomethyl)Amino]Ethyl}-1,4,7,10,13,16,19-Heptaazacyclotricosan-21-Yl]Amino}-3-{[3-Hydroxy-2-({2-[(6-Methyloctanoyl)Amino]-4-[(Sulfonatomethyl)Amino]Butanoyl}Amino)Butanoyl]Amino}-4-Oxobutyl)Amino]Methanesulfonate
Colistimethate sodium is a polymyxin B antibiotic that inhibits bacterial growth by binding to the cell membrane. It is used in the treatment of chronic pulmonary infections, as well as infections of the urinary tract and the skin caused by bacteria resistant to other antibiotics. Colistimethate sodium has been shown to be nebulized for the treatment of infectious diseases in geriatric patients, such as pneumonia and cystic fibrosis. This drug also has been shown to be effective against some strains of Aerobacter aerogenes. Colistin-resistant mutants have been found in clinical isolates, including strains resistant to colistin monotherapy or polymyxin B alone.